Drug Trial Radar · NCT04786964
Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC
Last checked: Nov 20, 2026Latest source record: Apr 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
25
Actual
Start
Dec 8, 2021
Primary completion
Dec 30, 2023
Study completion Dec 30, 2023
Sponsor
- Lead sponsor
- Checkpoint Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 8, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an efficacy and safety study of cosibelimab (CK-301) combined with pemetrexed/platinum chemotherapy versus pemetrexed/platinum chemotherapy alone in participants with advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have not previously received systemic therapy for advanced disease. Participants will be randomly assigned in a 2:1 ratio to receive cosibelimab combined with pemetrexed/platinum (Investigators choice of cisplatin or carboplatin), OR pemetrexed/platinum (Investigators choice of cisplatin or carboplatin). The primary hypothesis is that cosibelimab in combination with pemetrexed/platinum chemotherapy prolongs Overall Survival (OS) compared to pemetrexed/platinum chemotherapy alone.
Conditions
- Metastatic Non-squamous Non Small Cell Lung Cancer
Interventions
CosibelimabDrug
IV infusion
CisplatinDrug
IV infusion
CarboplatinDrug
IV infusion
PemetrexedDrug
IV infusion
Folic acid 350-1000 μgDietary supplement
Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
Vitamin B12 1000 μgDietary supplement
Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
Dexamethasone 4mgDrug
For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Approximately 3 years.
Locations
22 sites in 8 countries. Site status is shown where the registry gives one.
Research Site
Vitória, Brazil
Research Site
Tbilisi, Georgia
Research Site
Kota Bharu, Malaysia
Research Site
Wellington, New Zealand
Research Site
Lima, Peru
Research Site
Arkhangelsk, Russia
Research Site
Chelyabinsk, Russia
Research Site
Kaliningrad, Russia
Research Site
Kazan', Russia
Research Site
Kursk, Russia
Research Site
Kuzmolovskiy, Russia
Research Site
Moscow, Russia
Research Site
Nizhny Novgorod, Russia
Research Site
Novosibirsk, Russia
Research Site
Omsk, Russia
Research Site
Saint Petersburg, Russia
Research Site
Samara, Russia
Research Site
Sochi, Russia
Research Site
Tomsk, Russia
Research Site
Volgograd, Russia
Research Site
Pretoria, South Africa
Research Site
Chiang Mai, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.